Senator Rand Paul's Bill Aims to Fast-Track Biosimilar Approvals and Cut Costs

Senator Rand Paul’s Expedited Access to Biosimilars Act received a unanimous vote in the Senate Health, Education, Labor, and Pensions Committee. The bill would codify existing FDA guidance permitting biosimilar approval after analytical testing shows comparable metabolism to the reference biologic, eliminating the need for costly full clinical trials. Advocates point out that no biosimilar rejected after such testing has ever failed FDA approval, indicating the trials are redundant.

Former FDA commissioner Martin Makary estimates the reforms could cut development costs by as much as $150 million and accelerate market entry by two to four years. Biosimilars already cost 15-35 percent less than brand-name drugs, and their presence typically forces original manufacturers to lower prices. By speeding approvals, the legislation is expected to improve patient access and further drive down medication costs.